Home » Stocks » IMCR

Immunocore Holdings Limited (IMCR)

Stock Price: $41.25 USD -8.06 (-16.35%)
Updated Mar 4, 2021 4:00 PM EST - Market closed
After-hours: $41.20 -0.05 (-0.12%) Mar 4, 5:55 PM
Market Cap 2.09B
Revenue (ttm) 36.61M
Net Income (ttm) -104.89M
Shares Out 41.72M
EPS (ttm) -2.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $41.25
Previous Close $49.31
Change ($) -8.06
Change (%) -16.35%
Day's Open 49.15
Day's Range 40.00 - 49.15
Day's Volume 112,035
52-Week Range 39.02 - 61.99


Benzinga - 1 week ago

The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresecta...

About IMCR

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cance... [Read more...]

IPO Date
Feb 5, 2021
Bahija Jallal, Ph.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, Immunocore's revenue was 25.67 million, an increase of 8.52% compared to the previous year's 23.65 million. Losses were -103.93 million, 45.1% more than in 2018.

Financial numbers in millions GBP.
Financial Statements